Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY67U8)

• Drug Name: Trapidil Drug Info
• Synonyms: trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Phase 4	[1]
Coronary artery disease	BA80	Phase 4	[1]
Multiple myeloma	2A83	Investigative	[2]

• Cross-matching ID:
  PubChem CID: 5531
  ChEBI ID: CHEBI:32254
  CAS Number: CAS 15421-84-8
  TTD Drug ID: DMY67U8

Molecule-Related Drug Atlas

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[5]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[6]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[7]
Rosiglitazone + metformin	DMPIDXT	Diabetic complication	5A2Y	Phase 3	[4]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[4]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[4]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[8]
Vorolanib	DMIM1U9	Non-small cell lung cancer	2C25	Phase 2	[9]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[10]

Drug(s) Targeting Fibroblast growth factor receptor 3 (FGFR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[11]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[12]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[4]
BMS-582664	DMDAN8H	Hepatocellular carcinoma	2C12.02	Phase 3	[4]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
B-701	DMOMDA4	Bladder cancer	2C94	Phase 2	[14]
Recifercept	DML8N3Y	Achondroplasia	LD24.00	Phase 2	[15]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[16]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
Anti-FGFR3	DM6QENU	Multiple myeloma	2A83	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor 3 (FGFR3)	TTST7KB	FGFR3_HUMAN	Inhibitor	[2]
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health.
• [2] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [3] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [4] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [8] National Cancer Institute Drug Dictionary (drug id 695817).
• [9] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [10] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
• [16] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [17] Clinical pipeline report, company report or official report of Genentech (2011).